The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. RESULTS: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of CATT participants (>92%) had stable or improved VA relative to baseline.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).1”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this remarkable clinical effect, there was a wide range in treatment response.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“At one year, participants treated monthly with bevacizumab or ranibizumab gained 8.0 and 8.5 letters, respectively, and those treated as needed gained 5.9 and 6.8 letters, respectively.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,009
Zarembinski, T. I., Doty, N. J., Erickson, I. E., Srinivas, R., Wirostko, B. M., & Tew, W. P. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.09.029 · Cited by 66
Toth, C. A., DeCroos, F. C., Ying, G., Stinnett, S. S., Heydary, C. S., Burns, R., Maguire, M. G., Martín, D., & Jaffe, G. J. (2015) · Retina · doi:10.1097/iae.0000000000000483 · Cited by 67
Kitchens, J. W., Diana, V., Boyer, D. S., Thompson, D. E., Gibson, A., Saroj, N., Vitti, R., Berliner, A. J., & Kaiser, P. K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.046 · Cited by 67
Lim, L. S., Cheung, C. M. G., Mitchell, P., & Wong, T. Y. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.05.040 · Cited by 66
Curtis, L. H., Hammill, B. G., Qualls, L. G., Dimartino, L. D., Wang, F., Schulman, K. A., & Cousins, S. W. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.11.032 · Cited by 64
Tozer, K. R., Roller, A. B., Chong, L. P., Sadda, S. R., Folk, J. C., Mahajan, V. B., Russell, S. R., Boldt, H. C., & Sohn, E. H. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.016 · Cited by 65
Joussen, A. M., Wolf, S., Kaiser, P. K., Boyer, D. S., Schmelter, T., Sandbrink, R., Zeitz, O., Deeg, G., Richter, A., Zimmermann, T., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13794 · Cited by 63
CD11c+ macrophages are proangiogenic and necessary for experimental choroidal neovascularization
Droho, S., Rajesh, A., Cuda, C. M., Perlman, H., & Lavine, J. A. (2023) · JCI Insight · doi:10.1172/jci.insight.168142 · Cited by 64
VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration
Callan, A., Heckman, J., Tah, G., Lopez, S., Valdez, L., & Tsin, A. T. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114992 · Cited by 76
Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration
Ueta, T., Noda, Y., Toyama, T., Yamaguchi, T., & Amano, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.022 · Cited by 66
Sterile Endophthalmitis after Intravitreal Injections
Marticorena, J., Romano, V., & Gómez‐Ulla, F. (2012) · Mediators of Inflammation · doi:10.1155/2012/928123 · Cited by 64
CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION
Vélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Mandava, N., & Quiroz-Mercado, H. (2012) · Retina · doi:10.1097/iae.0b013e318271f265 · Cited by 69
Adrean, S. D., Chaili, S., Grant, S., & Pirouz, A. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.07.009 · Cited by 65
Carnevali, A., Sacconi, R., Querques, L., Marchese, A., Capuano, V., Rabiolo, A., Corbelli, E., Panozzo, G., Mière, A., Souied, E. H., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.02.002 · Cited by 65
Chuang, Y.-L., Fang, H.-W., Ajitsaria, A., Chen, K.-H., Su, C.-Y., Liu, G., & Tseng, C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11120635 · Cited by 65
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye
Cheng, K., Hsieh, C., Nepali, K., & Liou, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01033 · Cited by 69
Direct Comparison of Administration Routes for AAV8-mediated Ocular Gene Therapy
Igarashi, T., Miyake, K., Asakawa, N., Miyake, N., Shimada, T., & Takahashi, H. (2013) · Current Eye Research · doi:10.3109/02713683.2013.779720 · Cited by 64
Controlled-release nanotherapeutics: State of translation
Tan, Y., Lao, L. L., Xiong, G. M., & Venkatraman, S. S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.014 · Cited by 66
Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies
Kodjikian, L., Bellocq, D., & Mathis, T. (2018) · BioMed Research International · doi:10.1155/2018/8289253 · Cited by 64
Regional differences in the global burden of age-related macular degeneration
Xu, X., Wu, J., Yu, X., Tang, Y., Tang, X., & Shentu, X. (2020) · BMC Public Health · doi:10.1186/s12889-020-8445-y · Cited by 64
Sadda, S. R., Abdelfattah, N. S., Lei, J., Shi, Y., Marion, K. M., Morgenthien, E. A., Gune, S., & Balasubramanian, S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.031 · Cited by 67
Rush, R. B. (2023) · Clinical ophthalmology · doi:10.2147/opth.s424315 · Cited by 67
Intravitreal injections: a review of the evidence for best practice
Fagan, X. J., & Al‐Qureshi, S. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12026 · Cited by 64
Cho, H. J., Kim, J. W., Lee, D. W., Cho, S. W., & Kim, C. G. (2011) · Eye · doi:10.1038/eye.2011.324 · Cited by 64
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
Ohr, M. P., & Kaiser, P. K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.658368 · Cited by 64
Advances in Age-related Macular Degeneration Understanding and Therapy
Miller, J. W., Bagheri, S., & Vavvas, D. G. (2017) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2017.10.02.119 · Cited by 68
Framme, C., Eter, N., Hamacher, T., Hasanbasic, Z., Jochmann, C., Johnson, K. T. M., Kahl, M., Sachs, H. G., Schilling, H., Thelen, U., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.09.017 · Cited by 63
Bailey, C., Scott, L. J., Rogers, C. A., Reeves, B. C., Hamill, B., Pető, T., Chakravarthy, U., & Harding, S. P. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.013 · Cited by 64
Costagliola, C., Agnifili, L., Arcidiacono, B., Duse, S., Fasanella, V., Mastropasqua, R., Verolino, M., & Semeraro, F. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707176 · Cited by 63
Ramakrishnan, M. S., Yu, Y., & VanderBeek, B. L. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.4577 · Cited by 63
Han, X., Ong, J., Hewitt, A. W., Gharahkhani, P., & MacGregor, S. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa178 · Cited by 66
Hanson, R. L. W., Airody, A., Sivaprasad, S., & Gale, R. P. (2022) · Eye · doi:10.1038/s41433-022-02360-4 · Cited by 68
VEGFA and VEGFR2 Gene Polymorphisms and Response to Anti–Vascular Endothelial Growth Factor Therapy
Hagstrom, S. A., Ying, G., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Maguire, M. G., & Martin, D. F. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.109 · Cited by 63
Wickremasinghe, S., Janakan, V., Sandhu, S. S., Islam, A. F. M., Abedi, F., & Guymer, R. H. (2015) · Retina · doi:10.1097/iae.0000000000000902 · Cited by 62
Minion, L. E., Bai, J., Monk, B. J., Keller, L. R., Ramez, E. N., Forde, G. K., Chan, J. K., & Tewari, K. S. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.027 · Cited by 64
Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Cancarini, A., & Costagliola, C. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666151001120831 · Cited by 63
Thulliez, M., Angoulvant, D., Pisella, P., & Bejan‐Angoulvant, T. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.0002 · Cited by 62
Wan, C.-R., Muya, L. W., Kansara, V. S., & Ciulla, T. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020288 · Cited by 63
Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity
Hartnett, M. E. (2014) · Clinics in Perinatology · doi:10.1016/j.clp.2014.08.011 · Cited by 61
Ford, J. A., Elders, A., Shyangdan, D., Royle, P., & Waugh, N. R. (2012) · BMJ · doi:10.1136/bmj.e5182 · Cited by 61
Mantel, I., Deli, A., Iglesias, K., & Ambresin, A. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2090-9 · Cited by 60
Khanani, A. M., Eichenbaum, D. A., Schlottmann, P. G., Tuomi, L., & Sarraf, D. (2018) · Retina · doi:10.1097/iae.0000000000002195 · Cited by 61
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Bro, T., Derebecka, M., Jørstad, Ø. K., & Grzybowski, A. E. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04569-8 · Cited by 61
English, H., Hong, J., & Ho, M. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa001 · Cited by 61
Ophthalmology 1 Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · Cited by 60
Chaudhary, V., Matonti, F., Zarranz‐Ventura, J., & Stewart, M. W. (2021) · Retina · doi:10.1097/iae.0000000000003283 · Cited by 60
Das, U. N. (2012) · Nutrition · doi:10.1016/j.nut.2012.02.003 · Cited by 60
Hjelmqvist, L., Lindberg, C., Kanulf, P., Dahlgren, H., Johansson, I., & Siewert, A. (2011) · Journal of Ophthalmology · doi:10.1155/2011/405724 · Cited by 61
Chhablani, J. K., Kozak, I., Pichi, F., Chenworth, M. L., Berrocal, M. H., Bedi, R., Singh, R. P., Wu, L., MEYERLE, C. B., Casella, A., et al. (2015) · Retina · doi:10.1097/iae.0000000000000655 · Cited by 60
Cho, H. J., Kim, K. M., Kim, H. S., Lee, D. W., Kim, C. G., & Kim, J. W. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.03.039 · Cited by 60
Ye, H., Zhang, Q., Liu, X., Cai, X., Yu, W., Yu, S., Wang, T., Lu, W., Li, X., Jin, H., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14899 · Cited by 61
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture
Miller, J. W. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.2.9 · Cited by 62
Nagai, N., Suzuki, M., Uchida, A., Kurihara, T., Kamoshita, M., Minami, S., Shinoda, H., Tsubota, K., & Ozawa, Y. (2016) · Scientific Reports · doi:10.1038/srep29619 · Cited by 60
Zhou, Y., Zhou, M., Xia, S., Jing, Q., & Gao, L. (2016) · Scientific Reports · doi:10.1038/srep39301 · Cited by 61
Use of rabbit eyes in pharmacokinetic studies of intraocular drugs
Ahn, S. J., Hong, H. K., Na, Y. M., Park, S. J., Ahn, J., Oh, J., Chung, J. Y., Park, K. H., & Woo, S. J. (2016) · Journal of Visualized Experiments · doi:10.3791/53878 · Cited by 60
Drugs in Phase II clinical trials for the treatment of age-related macular degeneration
Tolentino, M. J., Dennrick, A., John, E. S., & Tolentino, M. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.961601 · Cited by 60
Ciulla, T. A., Hussain, R. M., Taraborelli, D., Pollack, J. S., & Williams, D. F. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.03.021 · Cited by 62
Cachafeiro, M. C. B., Bemelmans, A., Samardzija, M., Afanasieva, T. A., Pournaras, J.-A., Grimm, C., Kostic, C., Philippe, S., Wenzel, A., & Arsenijévic, Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.303 · Cited by 60
Li, Y., Liu, X., Zhou, T., Kelley, M. R., Edwards, P. A., Gao, H., & Qiao, X. (2014) · Redox Biology · doi:10.1016/j.redox.2014.01.023 · Cited by 59
Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration
Mueller, S., Agostini, H. T., Ehlken, C., Bauer-Steinhusen, U., Hasanbasic, Z., & Wilke, T. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.001 · Cited by 59
Anti-angiogenic Therapy for Retinal Disease
Paulus, Y. M., & Sodhi, A. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_78 · Cited by 60
Dugel, P. U., Boyer, D. S., Antoszyk, A. N., Steinle, N. C., Varenhorst, M. P., Pearlman, J. A., Gillies, M. C., Finger, R. P., Baldwin, M. E., & Leitch, I. M. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.10.008 · Cited by 60
Cheung, C. M. G., Li, X., Mathur, R., Lee, S. Y., Chan, C. M., Yeo, I. Y. S., Loh, B. K., Williams, R. E., Wong, E. Y., Wong, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101057 · Cited by 58
González‐López, J. J., McGowan, G., Chapman, E. A., & Yorston, D. (2016) · Eye · doi:10.1038/eye.2016.65 · Cited by 58
Mathis, T., Holz, F. G., Sivaprasad, S., Yoon, Y. H., Eter, N., Chen, L.-J., Koh, A. C., de Souza, E. C., & Staurenghi, G. (2022) · Eye · doi:10.1038/s41433-022-02231-y · Cited by 57
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis
Virgili, G., Curran, K., Lucenteforte, E., Pető, T., & Parravano, M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007419.pub7 · Cited by 65
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 66
Broadhead, G., Hong, T., & Chang, A. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12463 · Cited by 60
Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
Erol, M. K., Coban, D. T., Sarı, E. S., Bilgin, A. B., Doğan, B., Özdemir, Ö., & Tunay, Z. Ö. (2015) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20150090 · Cited by 58
Kim, S., Kambhampati, S. P., Bhutto, I. A., McLeod, D. S., Lutty, G. A., & Kannan, R. M. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108391 · Cited by 60
Yun, H., Yee, M. B., Lathrop, K. L., Kinchington, P. R., Hendricks, R. L., & Leger, A. J. S. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.013 · Cited by 54
Ghanchi, F. D., Bourne, R., Downes, S. M., Gale, R. P., Rennie, C. A., Tapply, I. H., & Sivaprasad, S. (2022) · Eye · doi:10.1038/s41433-021-01766-w · Cited by 58
Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection
Yannuzzi, N. A., Klufas, M. A., Quach, L., Beatty, L. M., Kaminsky, S. M., Crystal, R. G., D’Amico, D. J., & Kiss, S. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.3591 · Cited by 57
Ehlers, J. P., Petkovsek, D. S., Yuan, A., Singh, R. P., & Srivastava, S. K. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150323-05 · Cited by 57
Diabetic angiopathy and angiogenic defects
Xu, L., Kanasaki, K., Kitada, M., & Koya, D. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-13 · Cited by 58
Ferreira, A., Sagkriotis, A., Olson, M. S., Lu, J., Makin, C., & Milnes, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133968 · Cited by 56
Lanzetta, P., Mitchell, P., Wolf, S., & Veritti, D. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303394 · Cited by 58
Parke, D. W., Lum, F., & Rich, W. L. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0265-1 · Cited by 57
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials
Ying, G., Maguire, M. G., Pan, W., Grunwald, J. E., Daniel, E., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., & Martín, D. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.10.003 · Cited by 59
The Proteomic Landscape in the Vitreous of Patients With Age-Related and Diabetic Retinal Disease
Schori, C., Trachsel, C., Grossmann, J., Zygoula, I., Barthelmes, D., & Grimm, C. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24122 · Cited by 57
Gharbiya, M., Iannetti, L., Parisi, F., Vico, U. D., Mungo, M. L., & Marenco, M. (2014) · BioMed Research International · doi:10.1155/2014/273754 · Cited by 56
Kodjikian, L., Parravano, M., Clemens, A., Dolz‐Marco, R., Holz, F. G., Munk, M. R., Nicolò, M., Ricci, F., da Silva, R. M., Talks, J. S., et al. (2021) · Eye · doi:10.1038/s41433-021-01487-0 · Cited by 57
Automated Detection of Off-Label Drug Use
Jung, K., LePendu, P., Chen, W. S., Iyer, S. V., Readhead, B., Dudley, J. T., & Shah, N. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089324 · Cited by 56
Mousa, S. A., Thomas, & Mousa, S. A. (2013) · Clinical ophthalmology · doi:10.2147/opth.s29974 · Cited by 56
Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
Tsujikawa, A., Ellabban, A. A., Ogino, K., Ooto, Yamashiro, K., Oishi, A., & Yoshimura (2012) · Clinical ophthalmology · doi:10.2147/opth.s30907 · Cited by 56
Early detection of age related macular degeneration: current status
Schwartz, R., & Loewenstein, A. (2015) · International Journal of Retina and Vitreous · doi:10.1186/s40942-015-0022-7 · Cited by 58
Reibaldi, M., Pulvirenti, A., Avitabile, T., Bonfiglio, V. M. E., Russo, A., Mariotti, C., Bucolo, C., Mastropasqua, R., Parisi, G., & Longo, A. (2017) · Retina · doi:10.1097/iae.0000000000001583 · Cited by 56
Recent Advances in the Management of Neovascular Glaucoma
SooHoo, J. R., Seibold, L. K., & Kahook, M. Y. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2012.730103 · Cited by 56
Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice
Pinheiro-Costa, J., Costa, J. M. M., Beato, J. N., Freitas‐da‐Costa, P., Brandão, E., Falcão, M. S., Falcão‐Reis, F., & Carneiro, Â. M. (2015) · Ophthalmologica · doi:10.1159/000381221 · Cited by 58
Ristau, T., Keane, P. A., Walsh, A. C., Engin, A., Mokwa, N., Kirchhof, B., Sadda, S. R., & Liakopoulos, S. (2013) · Ophthalmologica · doi:10.1159/000354551 · Cited by 55
Paul, M., Vieillard, V., Roumi, E., Cauvin, A., Despiau, M.-C., Laurent, M., & Astier, A. (2012) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2012.03.006 · Cited by 55
Beyond VEGF—The Weisenfeld Lecture
Miller, J. W. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21201 · Cited by 56
Huang, J., Wang, W., Yu, J., Yu, X., Zheng, Q., Peng, F., He, Z., Zhao, W., Zhang, Z., Li, X., et al. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.07.057 · Cited by 55
Wecker, T., Grundel, B., Reichl, S., Stech, M., Lange, C., Agostini, H. T., Böhringer, D., & Stahl, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-38934-8 · Cited by 52
Lupo, G., Cambria, M. T., Olivieri, M., Rocco, C., Caporarello, N., Longo, A., Zanghì, G., Salmeri, M., Foti, M. C., & Anfuso, C. D. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14455 · Cited by 57
Jackson, T. L., Slakter, J., Buyse, M., Wang, K., Dugel, P. U., Wykoff, C. C., Boyer, D. S., Gerometta, M., Baldwin, M. E., Price, C. F., et al. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.02.001 · Cited by 55
AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration
Liu, Y., Fortmann, S. D., Shen, J., Wielechowski, E., Tretiakova, A., Yoo, S., Kozarsky, K., Wang, J., Wilson, J. M., & Campochiaro, P. A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.002 · Cited by 51
Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy
Watson, N., & Al-Samkari, H. T. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15354 · Cited by 56
Channa, R., Sophie, R., Bagheri, S., Shah, S. M., Wang, J., Adeyemo, O., Sodhi, A., Wenick, A. S., Ying, H. S.-C., & Campochiaro, P. A. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.09.012 · Cited by 54
Muether, P. S., Hermann, M. M., Dröge, K., Kirchhof, B., & Fauser, S. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.06.020 · Cited by 54
Metadata
- Authors
- The CATT Research Group
- Corresponding author
- The CATT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3157322
- OpenAlex
- W1481978003
- Cited by
- 2,669
- References
- 21
- Citations by year
- 2026: 78 · 2025: 91 · 2024: 116 · 2023: 111 · 2022: 127 · 2021: 164 · 2020: 195 · 2019: 151 · 2018: 168 · 2017: 177 · 2016: 199 · 2015: 238 · 2014: 264 · 2013: 248 · 2012: 265
- FWCI
- 254.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, intravitreal injection, anti-VEGF therapy, visual acuity, central retinal thickness, treatment schedule, non-inferiority, serious adverse events, off-label drug use, anti-angiogenic therapy, comparative efficacy and safety, hospitalization
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cardiovascular Diseases, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Middle Aged, Retina, Therapeutic Equivalency, Visual Acuity, Proportional Hazards Models, Single-Blind Method, Off-Label Use, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
